Mohsen Honarpisheh

Mohsen Honarpisheh

Auto-generated profile, based on publicly available information

Mohsen Honarpisheh

Medizinische Klinik und Poliklinik IV, Diabetes Zentrum, Klinikum der Universität München, LMU Munich, Munich, Germany

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
QMQiuyue Ma
Qiuyue Ma
MHMohsen Honarpisheh
Mohsen Honarpisheh
LCLi Chenyu
Li Chenyu
MSMarkus Sellmayr
Markus Sellmayr
MLMaja Lindenmeyer
Maja Lindenmeyer
Stefanie SteigerStefanie Steiger
Stefanie Steiger
Although monosodium urate (MSU) crystals are known to trigger inflammation, published data on soluble uric acid (sUA) in this context are discrepant. We hypothesized that diverse sUA preparation methods account for this discrepancy and that an animal model with clinically relevant levels of asymptomatic hyperuricemia and gouty arthritis can ultimately clarify this issue. To test this, we cultured human monocytes with different sUA preparation solutions and found that solubilizing uric acid (UA) by prewarming created erroneous results because of UA microcrystal contaminants triggering IL-1β release. Solubilizing UA with NaOH avoided this artifact, and this microcrystal-free preparation suppressed LPS- or MSU crystal–induced monocyte activation, a process depending on the intracellular uptake of sUA via the urate transporter SLC2A9/GLUT9. CD14+ monocytes isolated from hyperuricemic patients were less responsive to inflammatory stimuli compared with monocytes from healthy individuals. Treatment with plasma from hyperuricemic patients impaired the inflammatory function of CD14+ monocytes, an effect fully reversible by removing sUA from hyperuricemic plasma. Moreover, Alb-creERT2;Glut9lox/lox mice with hyperuricemia (serum UA of 9–11 mg/dl) showed a suppressed inflammatory response to MSU crystals compared with Glut9lox/lox controls without hyperuricemia. Taken together, we unravel a technical explanation for discrepancies in the published literature on immune effects of sUA and identify hyperuricemia as an intrinsic suppressor of innate immunity, in which sUA modulates the capacity of monocytes to respond to danger signals. Thus, sUA is not only a substrate for the formation of MSU crystals but also an intrinsic inhibitor of MSU crystal–induced tissue inflammation. Key Points Soluble but not crystalline UA acts as a negative regulator of innate immunity. sUA suppresses activated monocytes via SLC2A9-mediated intracellular uptake. Asymptomatic HU attenuates MSU crystal–induced tissue inflammation.

8 May 2018 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
MHMohsen Honarpisheh
Mohsen Honarpisheh
PKPaulina Köhler
Paulina Köhler
EREkaterina von Rauchhaupt
Ekaterina von Rauchhaupt
Maciej LechMaciej Lech
Maciej Lech
Noncoding RNAs (ncRNAs), including microRNAs (miRNAs), represent a family of RNA molecules that do not translate into protein. Nevertheless, they have the ability to regulate gene expression and play an essential role in immune cell differentiation and function. MicroRNAs were found to be differentially expressed in various tissues, and changes in their expression have been associated with several pathological processes. Yet, their roles in systemic lupus erythematosus (SLE) and lupus nephritis (LN) remain to be elucidated. Both SLE and LN are characterized by a complex dysfunction of the innate and adaptive immunity. Recently, significant findings have been made in understanding SLE through the use of genetic variant identification and expression pattern analysis and mouse models, as well as epigenetic analyses. Abnormalities in immune cell responses, cytokine and chemokine production, cell activation, and apoptosis have been linked to a unique expression pattern of a number of miRNAs that have been implicated in the immune pathogenesis of this autoimmune disease. The recent evidence that significantly increased the understanding of the pathogenesis of SLE drives a renewed interest in efficient therapy targets. This review aims at providing an overview of the current state of research on the expression and role of miRNAs in the immune pathogenesis of SLE and LN.

15 August 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MHMohsen Honarpisheh
Mohsen Honarpisheh
OFOrestes Foresto-Neto
Orestes Foresto-Neto
Stefanie SteigerStefanie Steiger
Stefanie Steiger
FKFranziska Kraft
Franziska Kraft
PKPaulina Koehler
Paulina Koehler
Maciej LechMaciej Lech
Maciej Lech
Acute and chronic kidney injuries are multifactorial traits that involve various risk factors. Experimental animal models are crucial to unravel important aspects of injury and its pathophysiological mechanisms. Translating knowledge obtained from experimental approaches into clinically useful information is difficult; therefore, significant attention needs to be paid to experimental procedures that mimic human disease. Herein, we compared aristolochic acid I (AAI) acute and chronic kidney injury model with unilateral ischemic-reperfusion injury (uIRI), cisplatin (CP)- or folic acid (FA)-induced renal damage. The administration of AAI showed significant changes in serum creatinine and BUN upon CKD. The number of neutrophils and macrophages were highly increased as well as AAI-induced CKD characterized by loss of tubular epithelial cells and fibrosis. The in vitro and in vivo data indicated that macrophages play an important role in the pathogenesis of AA-induced nephropathy (AAN) associated with an excessive macrophage accumulation and an alternative activated macrophage phenotype. Taken together, we conclude that AA-induced injury represents a suitable and relatively easy model to induce acute and chronic kidney injury. Moreover, our data indicate that this model is appropriate and superior to study detailed questions associated with renal macrophage phenotypes.

15 August 2017 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
Stefanie SteigerStefanie Steiger
Stefanie Steiger
SKSanthosh Vr Kumar
Santhosh Vr Kumar
MHMohsen Honarpisheh
Mohsen Honarpisheh
GLGeorg Lorenz
Georg Lorenz
RGRoman Günthner
Roman Günthner
Maciej LechMaciej Lech
Maciej Lech
Activation of various innate immune receptors results in IL-1 receptor–associated kinase (IRAK)-1/IRAK-4–mediated signaling and secretion of proinflammatory cytokines such as IL-12, IL-6, or TNF-α, all of which are implicated in tissue injury and elevated during tissue remodeling processes. IRAK-M, also known as IRAK-3, is an inhibitor of proinflammatory cytokine and chemokine expression in intrarenal macrophages. Innate immune activation contributes to both acute kidney injury and tissue remodeling that is associated with chronic kidney disease (CKD). Our study assessed the contribution of macrophages in CKD and the role of IRAK-M in modulating disease progression. To evaluate the effect of IRAK-M in chronic renal injury in vivo, a mouse model of unilateral ureteral obstruction (UUO) was employed. The expression of IRAK-M increased within 2 d after UUO in obstructed compared with unobstructed kidneys. Mice deficient in IRAK-M were protected from fibrosis and displayed a diminished number of alternatively activated macrophages. Compared to wild-type mice, IRAK-M–deficient mice showed reduced tubular injury, leukocyte infiltration, and inflammation following renal injury as determined by light microscopy, immunohistochemistry, and intrarenal mRNA expression of proinflammatory and profibrotic mediators. Taken together, these results strongly support a role for IRAK-M in renal injury and identify IRAK-M as a possible modulator in driving an alternatively activated profibrotic macrophage phenotype in UUO-induced CKD.

31 August 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
YLYutian Lei
Yutian Lei
LBLelia Wolf-Van Buerck
Lelia Wolf-Van Buerck
MHMohsen Honarpisheh
Mohsen Honarpisheh
YZYicheN ZhanG
YicheN ZhanG
RSReinhard Schwinzer
Reinhard Schwinzer
JSJochen Seissler
Jochen Seissler
Strong xenorejection limits the clinical application of porcine islet transplantation in type 1 diabetes. Targeting T cell-mediated rejection is one of the main approaches to improve long-term graft survival. Here we study engraftment and survival of porcine islet cells expressing human programmed death-ligand 1 (hPD-L1) in a humanized mouse model. Neonatal islet-like clusters (NPICCs) from transgenic hPD-L1 (hPD-L1-Tg) and wild-type (Wt) pigs were transplanted into diabetic NOD-scid IL2Rγnull mice stably reconstituted with human immune cells (hPD-L1 n=10; Wt n=6). Primary endpoint was development of normoglycemia during a 16 weeks observation period after transplantation. Secondary endpoints were porcine C-peptide levels and immune cell infiltration. Animals transplanted with hPD-L1-Tg NPICCs achieved superior normoglycemic rate (50% versus 0%) and significantly higher plasma C-peptide levels as compared to the Wt group indicating long-term beta cell function. Intracytoplasmic FACS analysis and immunohistochemistry revealed significant decreased frequencies of IFNγ expressing splenic hCD8 positive T cells and reduced intragraft infiltrating immune cells. We here demonstrate that expression of hPD-L1-Tg provided a strong islet xenograft protection without administration of immunosuppressive drugs. These findings support the hypothesis that hPD-L1 has the capacity to control cellular rejection and therefore represent a very promising transgene candidates for clinical porcine islet xenotransplantation.

23 April 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
KBKevin Bellofatto
Kevin Bellofatto
FLFanny Lebreton
Fanny Lebreton
MHMasoud Hassany
Masoud Hassany
RHReine Hanna
Reine Hanna
JBJuliette Bignard
Juliette Bignard
VCVANGUARD consortium
VANGUARD consortium
Beta cell replacement therapy for type 1 diabetes is hindered by poor graft survival and suboptimal function, largely due to inadequate vascularization and lack of supportive microenvironment. To address these challenges, we developed a clinically scalable, extracellular matrix (ECM)–mimetic hydrogel, termed Amniogel, derived from human amniotic membrane via streamlined, clinically compliant process. Co-encapsulation of pancreatic islets with blood outgrowth endothelial cells (BOECs) within Amniogel facilitated the formation of prevascularized endocrine constructs (VECs). These constructs demonstrated enhanced β-cell viability and function through ECM-bound pro-survival signals, rapid self-assembly of perfusable endothelial networks enabling efficient glucose sensing, and deposition of laminin-rich basement membranes enhancing β-cell coupling and insulin secretion kinetics. In preclinical diabetic mouse models, VECs rapidly integrated with the host vasculature and provided sustained glycemic control when implanted subcutaneously. This integrative approach, combining a scalable, cost-effective biological scaffold with autologous vascularization potential, represents a significant advancement toward durable and clinically translatable β-cell replacement therapies for T1DM. One Sentence Summary: A clinically scalable, biological hydrogel based vascularized endocrine constructs show sustained diabetes reversal.